非小细胞肺癌患者阿米万他抗致肺炎2例

IF 3.5 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2025-02-12 DOI:10.1016/j.jtocrr.2025.100805

Alexander J. DeWeerd MD , Elizabeth Sun BS , Wade T. Iams MD, MSCI

{"title":"非小细胞肺癌患者阿米万他抗致肺炎2例","authors":"Alexander J. DeWeerd MD , Elizabeth Sun BS , Wade T. Iams MD, MSCI","doi":"10.1016/j.jtocrr.2025.100805","DOIUrl":null,"url":null,"abstract":"<div><div>Although drug-induced interstitial lung disease has been reported with cancer-directed antibody-drug conjugates and EGFR tyrosine kinase inhibitors, it remains a rare event in patients treated with amivantamab. In this report, we present two cases of suspected amivantamab-related drug-induced interstitial lung disease in patients with canonical EGFR mutant NSCLC after progression on osimertinib.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 7","pages":"Article 100805"},"PeriodicalIF":3.5000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Two Cases of Amivantamab-Induced Pneumonitis in Patients With NSCLC: Case Report\",\"authors\":\"Alexander J. DeWeerd MD , Elizabeth Sun BS , Wade T. Iams MD, MSCI\",\"doi\":\"10.1016/j.jtocrr.2025.100805\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Although drug-induced interstitial lung disease has been reported with cancer-directed antibody-drug conjugates and EGFR tyrosine kinase inhibitors, it remains a rare event in patients treated with amivantamab. In this report, we present two cases of suspected amivantamab-related drug-induced interstitial lung disease in patients with canonical EGFR mutant NSCLC after progression on osimertinib.</div></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":\"6 7\",\"pages\":\"Article 100805\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-02-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666364325000219\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364325000219","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

虽然药物诱导的间质性肺疾病已经有癌症导向的抗体-药物偶联物和EGFR酪氨酸激酶抑制剂的报道，但在阿米万他抗治疗的患者中仍然是罕见的事件。在本报告中，我们报告了两例可疑的阿米伐他麦相关药物诱导的典型EGFR突变NSCLC患者在服用奥西替尼后发生间质性肺疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Two Cases of Amivantamab-Induced Pneumonitis in Patients With NSCLC: Case Report

Although drug-induced interstitial lung disease has been reported with cancer-directed antibody-drug conjugates and EGFR tyrosine kinase inhibitors, it remains a rare event in patients treated with amivantamab. In this report, we present two cases of suspected amivantamab-related drug-induced interstitial lung disease in patients with canonical EGFR mutant NSCLC after progression on osimertinib.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊